ANALYSE NUMÉRIQUE D'ÉCHANTILLONS DE SANG POUR DÉTERMINER L'EFFICACITÉ DE THÉRAPIES ANTICANCÉREUSES POUR DES CANCERS SPÉCIFIQUES

摘要

This disclosure relates to new assay methods for analysis of RNA, e.g., from circulating tumor cells (CTCs), tumor-specific exosomes, or tumor-specific cell-free RNA, in a subject's blood sample to determine an expression level of one or more lineage markers in the blood sample, wherein the expression level of a specific one or more lineage markers is predictive of progression-free survival and overall survival for a specific anti-cancer treatment regimen in that subject.